$1.82
Today
as of Sep 4, 16:48 ET
Last 30 days
Recent Press Releases & News
enGene to Participate in Upcoming Investor Conferences
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
Overview
52-week range
$1.40
$12
4% of range
Avg surprise (last 2)
-9.2%
Avg reaction (last 1)
+0.9%
100% positive
Latest IV / EM
180%
EM ±29.1% · $2 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu Apr 30, 2026 | Apr 2026 | $-0.43 | — | — | — | — | financials |
| Sat Jan 31, 2026 | Jan 2026 | $0.44 | — | — | — | — | financials |
| Thu Sep 11, 2025 | Jul/2025 | $-0.57 | $-0.49 | -16.3% | — | — | earnings |
| Thu Jun 12, 2025 | Apr/2025 | $-0.51 | $-0.50 | -2.0% | — | +0.9% | earnings |
| Wed Apr 30, 2025 | Apr 2025 | $-0.51 | — | — | — | — | financials |
| Fri Jan 31, 2025 | Jan 2025 | $0.48 | — | — | — | — | financials |
| Wed Jul 31, 2024 | Jul 2024 | $0.32 | — | — | — | — | financials |
| Tue Apr 30, 2024 | Apr 2024 | $0.38 | — | — | — | — | financials |
| Wed Jan 31, 2024 | Jan 2024 | $0.46 | — | — | — | — | financials |
| Mon Jul 31, 2023 | Jul 2023 | $8.55 | — | — | — | — | financials |
| Sun Apr 30, 2023 | Apr 2023 | $9.30 | — | — | — | — | financials |
| Tue Jan 31, 2023 | Jan 2023 | $13.29 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Sep 10, 2026 | Jul/2026 | OTHER | -$0.47 | -$0.57 | +17.5% |
Financials
Income statement (quarterly)
| Metric | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-32M | $-31M | — | $-30M | $-27M | $-27M | — | $-17M |
| Net income | $-30M | $-30M | — | $-29M | $-26M | $-25M | — | $-14M |
| EPS (diluted) | $-0.43 | $0.44 | — | $0.57 | $-0.51 | $0.48 | — | $0.32 |
Balance sheet (quarterly)
| Metric | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $30M | $37M | $50M | $33M | $58M | $62M | $173M | $258M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $270M | $289M | $201M | $211M | $228M | $222M | $247M | $263M |
| Total assets | $308M | $337M | $221M | $246M | $267M | $286M | $311M | $267M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $52M | $56M | $54M | $45M | $39M | $36M | $39M | $37M |
| Total equity | $255M | $282M | $168M | $201M | $227M | $250M | $273M | $230M |